$HUMA is still flying under the radar.
FDA-approved platform, growing commercial footprint, and key clinical updates still ahead.
June could bring major attention back to this name.
High risk. High upside.
#HUMA#Biotech#StockMarket#Investing#Trading#FDA
You probably ignored $HUMA when I mentioned it weeks ago.
Now it’s up 70%+… and June catalysts are still ahead.
Bioengineered human tissue. Real FDA potential. Small cap.
Sometimes the market whispers before it moves.
#HUMA#Biotech#Stocks#SmallCaps
$ENGN just got crushed.
~80% down on clinical news, but this is exactly where I start watching closely.
enGene is working on non-viral gene therapy for bladder cancer, with FDA/BLA milestones still ahead.
Oversold? Maybe. Broken? Not always.
#ENGN#Biotech#Stocks#Trading
@amitisinvesting Why chase trillion-dollar companies for limited upside…
When small caps with real catalysts can deliver multiples?
As a small or mid-sized investor, asymmetric opportunities are where real wealth is built.
@YahooFinance Why chase trillion-dollar companies for limited upside…
When small caps with real catalysts can deliver multiples?
As a small or mid-sized investor, asymmetric opportunities are where real wealth is built.
@RyanDetrick Why chase trillion-dollar companies for limited upside…
When small caps with real catalysts can deliver multiples?
As a small or mid-sized investor, asymmetric opportunities are where real wealth is built.
@antibearthesis Why chase trillion-dollar companies for limited upside…
When small caps with real catalysts can deliver multiples?
As a small or mid-sized investor, asymmetric opportunities are where real wealth is built.
Why chase trillion-dollar companies for limited upside…
When small caps with real catalysts can deliver multiples?
As a small or mid-sized investor, asymmetric opportunities are where real wealth is built.
#SmallCaps#StockMarket#Investing#Trading#GrowthStocks
@HeroDividend When indexes run this hard into all-time highs, it doesn’t take much to trigger profit taking.
Momentum drives the rally. Liquidity drives the pullbacks.
$GUTS targets obesity & type 2 diabetes—one of the biggest healthcare markets.
Been watching it and buying since $0.40.
Still believe the upside is there if execution delivers.
#GUTS#Biotech#StockMarket#Trading#Investing
@antibearthesis Agreed — waiting forever for a crash can cost you.
But blindly buying at all-time highs without respecting macro risk can cost you too.
Timing and discipline still matter.
$ROLR is moving into prediction markets with https://t.co/rn02WjmJYM.
If execution delivers, this goes beyond a simple casino play.
Potentially a strong entry point here.
High risk. High potential.
#ROLR#StockMarket#Investing#Crypto#Trading
$CMPX — biotech with real upside potential.
After a major pullback, it’s trading near oversold levels while fundamentals and pipeline still hold.
Position built early. Now letting it play out.
High risk. High reward.
#CMPX#Biotech#StockMarket#Investing#Trading
$ROLR — been talking about this for a while.
Now up big, momentum confirmed.
This is what happens when you spot it early and stay patient.
Still believe there’s more upside if execution holds.
#ROLR#StockMarket#Trading#Investing#Momentum#Discipline